Clinical Efficacy and Safety of Camrelizumab Combined with Endostar in the Treatment of Advanced Non-small Cell Lung Cancer
Sun Liqiu
Yu Tingting
Wang Hongli
Abstract：Objective:To evaluate the efficacy and safety of the immune checkpoint inhibitors camrelizumab in combination with the recombinant human endostatin endostar in the treatment of advanced non-small cell lung cancer(NSCLC),and to explore the therapeutic approach of advanced NSCLC without chemotherapy.Methods:30 patients with advanced NSCLC admitted to Medical Oncology Department,Mudanjiang Tumor Hospital from April 2021 to April 2023 were selected.Eligible patients received camrelizumab in combination with endostar for l treatment cycle of 3 weeks.Toxicity was assessed after 1-week treatment cycle and efficacy after 3-week treatment cycles.Results:The objective response rate was 28.57％,the disease control rate was 71.43％,and median progression-free survival and median overall survival were 4.3 and 14 months,respectively.The overall improvement rate of quality of life was 71.43％.Adverse events that occurred during treatment were mostly grade Ⅰ～Ⅱ adverse reactions,and no treatment-related deaths occurred.Conclusion:The combination therapy of camrelizumab and endostar shows significant efficacy and manageable safety profile,which provides a promising treatment regimen for advanced NSCLC.
Keywords：ImmunotherapyAntiangiogenesis therapyAdvanced non-small cell lung cancer
Publication Date：2025-02-27
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 387-390 )